Who are DalCor www.dalcorpharma.com's investors?

DalCor www.dalcorpharma.com's investors include Sanderling Ventures.

DalCor www.dalcorpharma.com

Founded 2015 · 19 employees on LinkedIn · 1 known investors

Find your way into DalCor www.dalcorpharma.com

Each arrow is one introduction. Sign up to fill in the first one.

478 people can intro you to Michael

Ask Paulette Taylor to introduce you to Michael Dixon

You →Paulette · together at Sanderling Ventures →Michael

Your email: who you already know at DalCor www.dalcorpharma.com, and who your contacts know
2nd- and 3rd-degree connections: people you know who worked, studied or invested with the DalCor www.dalcorpharma.com team
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

DalCor Pharmaceuticals is a biopharmaceutical company developing dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease that targets patients with the ADCY9 AA genotype. The drug is being evaluated in Phase 3 clinical trials to reduce fatal and non-fatal myocardial infarction in post-acute coronary syndrome patients.

Biotech Deep Tech Digital Health

Founders & leadership

Fouzia Laghrissi-ThodeChief Executive Officer

Michael Dixon Chief Financial OfficerMichael Dixon serves as Chief Financial Officer of DalCor Pharmaceuticals, a biopharmaceutical company developing precision medicines for cardiovascular disease.

Therese HeinonenChief Development Officer

Diane SullivanChief Commercial Officer

Investors · 1

Sanderling Ventureslisted by Sanderling VenturesSan Mateo · $50K – $1M

How we know: Sanderling Ventures's portfolio page · Not right? Tell us

Related companies · 5

Capricor TherapeuticsCapricor Therapeutics is a biotechnology company developing allogeneic cardiosphere-derived cell (CDC) and exosome-based therapeutics to treat serious diseases including Duchenne muscular dystrophy. The company uses cell and exosome biology platforms to create novel therapeutic medicines for patient treatment.

ArecorAreCor develops proprietary pharmaceutical products for diabetes, obesity, and cardiometabolic diseases using its Arestat technology platform. The company targets areas of high unmet patient need in high-value therapeutic markets.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

CeleCor TherapeuticsCelecor develops zalunfiban (Disaggpro), an investigational platelet inhibitor drug designed for rapid subcutaneous administration by first responders in pre-hospital treatment of STEMI heart attacks. The company focuses on acute cardiovascular care for patients experiencing the most severe form of heart attack.

XyloCor TherapeuticsXyloCor Therapeutics develops gene therapies for advanced coronary artery disease and cardiac damage. The company's lead program, XC001, targets refractory angina in patients with limited treatment options.

Companies working in the same space as DalCor www.dalcorpharma.com.

Frequently asked questions

What does DalCor www.dalcorpharma.com do?: DalCor Pharmaceuticals is a biopharmaceutical company developing dalcetrapib, a pharmacogenetic precision medicine for cardiovascular disease that targets patients with the ADCY9 AA genotype. The drug is being evaluated in Phase 3 clinical trials to reduce fatal and non-fatal myocardial infarction in post-acute coronary syndrome patients.
Who are DalCor www.dalcorpharma.com's investors?: DalCor www.dalcorpharma.com's investors include Sanderling Ventures.